Hikma Pharmaceuticals 관리
관리 기준 확인 2/4
Hikma Pharmaceuticals CEO는 Riad Mishlawi, Sep2023 에 임명되었습니다 의 임기는 1.17 년입니다. 총 연간 보상은 $ 1.55M, 21.5% 로 구성됩니다. 21.5% 급여 및 78.5% 보너스(회사 주식 및 옵션 포함). 는 £ 2.60M 가치에 해당하는 회사 주식의 0.06% 직접 소유합니다. 2.60M. 경영진과 이사회의 평균 재임 기간은 각각 1.2 년과 5.4 년입니다.
주요 정보
Riad Mishlawi
최고 경영자
US$1.6m
총 보상
| CEO 급여 비율 | 21.5% |
| CEO 임기 | 1.2yrs |
| CEO 소유권 | 0.06% |
| 경영진 평균 재임 기간 | 1.2yrs |
| 이사회 평균 재임 기간 | 5.4yrs |
최근 관리 업데이트
Recent updates
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$285m |
| Mar 31 2024 | n/a | n/a | US$238m |
| Dec 31 2023 | US$2m | US$333k | US$190m |
보상 대 시장: Riad 의 총 보상 ($USD 1.55M ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.23M ).
보상과 수익: Riad 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.
CEO
Riad Mishlawi (60 yo)
1.2yrs
테뉴어
US$1,552,833
보상
Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 17.3yrs | US$3.57m | 0.38% £ 16.6m | |
| CEO & Director | 1.2yrs | US$1.55m | 0.060% £ 2.6m | |
| Executive Vice Chairman & President of MENA | 19.2yrs | US$2.84m | 0.63% £ 27.1m | |
| Chief Financial Officer | 13.8yrs | 데이터 없음 | 0.20% £ 8.8m | |
| Chief Information Officer | no data | 데이터 없음 | 데이터 없음 | |
| Associate Director of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| General Counsel | no data | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Corporate Development and M&A | 10.7yrs | 데이터 없음 | 0.26% £ 11.2m | |
| Chief People Officer | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Strategic Planning & Global Affairs | 6.8yrs | 데이터 없음 | 데이터 없음 | |
| President of Injectables Business | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Quality Compliance/Health & Safety | less than a year | 데이터 없음 | 데이터 없음 |
1.2yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 관리: HIK 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 17.3yrs | US$3.57m | 0.38% £ 16.6m | |
| CEO & Director | 1.2yrs | US$1.55m | 0.060% £ 2.6m | |
| Executive Vice Chairman & President of MENA | 19.2yrs | US$2.84m | 0.63% £ 27.1m | |
| Senior Independent Non-Executive Director | 2yrs | US$149.27k | 데이터 없음 | |
| Independent Non-Executive Director | 8.1yrs | US$176.38k | 0.0032% £ 138.4k | |
| Independent Non-Executive Director | 8.7yrs | US$159.69k | 0.0016% £ 68.3k | |
| Non-Executive Director | 19.1yrs | US$116.72k | 0.52% £ 22.7m | |
| Independent Non-Executive Director | 4.5yrs | US$149.85k | 0.0020% £ 87.8k | |
| Independent Non-Executive Director | 2yrs | US$127.05k | 0.00045% £ 19.5k | |
| Independent Non-Executive Director | 5.4yrs | US$134.68k | 0.00050% £ 21.6k | |
| Chairman of West-ward Pharmaceuticals | no data | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 2.1yrs | US$124.98k | 데이터 없음 |
5.4yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: HIK 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.